Exelixis
EXEL
#1692
Rank
$11.94 B
Marketcap
$44.37
Share price
0.82%
Change (1 day)
24.04%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Operating Margin for Exelixis (EXEL)

Operating Margin as of December 2025 (TTM): 38.16%

According to Exelixis's latest financial reports and stock price the company's current Operating Margin is 38.16%. At the end of 2024 the company had an Operating Margin of 31.43%.

Operating Margin history for Exelixis from 2001 to 2025

Operating Margin at the end of each year

Year Operating Margin Change
202431.43%123.38%
202314.07%-3.27%
202214.55%-29.04%
202120.50%54.72%
202013.25%-67.79%
201941.14%-22.31%
201852.95%51.08%
201735.05%-195.55%
2016-36.68%-91.57%
2015-434.98%-58.23%
2014-1,041.29%33.27%
2013-781.34%151.29%
2012-310.93%-1269.7%
201126.58%-153.23%
2010-49.93%-46.19%
2009-92.81%-37.7%
2008-148.97%-12.86%
2007-170.96%33.08%
2006-128.46%2.92%
2005-124.81%-51.93%
2004-259.65%40.69%
2003-184.55%-3.24%
2002-190.73%13.94%
2001-167.39%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
GlaxoSmithKline
GSK
22.01%-42.32%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
15.12%-60.38%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
31.06%-18.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
16.72%-56.18%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
22.91%-39.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
18.78%-50.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
12.60%-66.98%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
-397.77%-1,142.37%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-30.78%-180.66%๐Ÿ‡บ๐Ÿ‡ธ USA

What is a company's Operating Margin?

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.